The agreement gives Zydus subsidiary Sentynl Therapeutics an option for exclusive US commercial and global manufacturing rights to Mereo BioPharma’s oral neutrophil elastase inhibitor, with Mereo leading preparations for pivotal development.

The agreement gives Sentynl an exclusive pathway to commercialise the Phase III-ready rare lung disease therapy in the US while providing global manufacturing rights and funding support for late-stage development.

The partnership gives Sobi potential global commercial and development rights to the first-in-class anti-KIR3DL2 antibody while funding Innate’s Phase III programme in cutaneous T-cell lymphoma.

The rights reversion gives Actimed full control of the muscle-wasting candidate across all indications, with amyotrophic lateral sclerosis remaining its primary development focus.

The agreement gives an undisclosed global pharmaceutical company worldwide rights to use Alteogen’s ALT-B4 technology to develop and commercialise a subcutaneous formulation of an existing biologic.

Pathos AI licenses first-in-class bispecific ADC JSKN016 from Alphamab Oncology in deal worth up to $4.8 billion

The spin-out creates a dedicated US oncology company to raise capital and advance Lupin’s PRMT5 and SOS1 programmes through global clinical development.

The agreement expands AstraZeneca’s oncology portfolio with an oral EGFR inhibitor for non-small-cell lung cancer, as Dizal seeks to broaden Zegfrovy’s use into earlier lines of treatment.

The agreement gives AstraZeneca exclusive rights to develop, manufacture and commercialise TQC3721 outside China.